Immune checkpoint inhibitors, such as anti PD-1 or PD-L1 antibodies, have been designed to target negative regulatory pathways of T cell activity, to boost or restore their anti-tumor function, and they have indeed been shown to achieve considerable clinical results, at least in specific tumor types, such as melanoma and lung cancer [11–13]. This evidence concerns the gene CD274 and neoplasm.